Jane Street Group LLC Purchases 3,732 Shares of Certara, Inc. (NASDAQ:CERT)

Jane Street Group LLC increased its position in Certara, Inc. (NASDAQ:CERT) by 2.6% during the third quarter, HoldingsChannel reports. The institutional investor owned 147,393 shares of the company’s stock after acquiring an additional 3,732 shares during the period. Jane Street Group LLC’s holdings in Certara were worth $1,726,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. State Street Corp increased its stake in shares of Certara by 3.4% during the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after purchasing an additional 122,411 shares during the last quarter. Petrus Trust Company LTA bought a new stake in Certara in the third quarter worth $994,000. Paloma Partners Management Co acquired a new position in Certara during the third quarter worth $413,000. 272 Capital LP acquired a new position in Certara during the third quarter worth $177,000. Finally, Wasatch Advisors LP raised its holdings in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Stock Down 0.4 %

CERT opened at $10.70 on Thursday. The business has a 50 day moving average of $10.78 and a 200-day moving average of $12.29. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -53.50, a P/E/G ratio of 5.86 and a beta of 1.53. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The company had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period last year, the business posted $0.06 EPS. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current year.

Insider Buying and Selling at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 9.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CERT shares. Robert W. Baird lowered their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Barclays lowered their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.